Bots, editor, reviewer, Administrators
13,951
edits
Feed:Trial Acronyms: Difference between revisions
Jump to navigation
Jump to search
no edit summary
No edit summary |
No edit summary |
||
| Line 8: | Line 8: | ||
"TACTICS-TIMI 18" : "Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban", | "TACTICS-TIMI 18" : "Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban", | ||
"EASE" : "Early Surgery versus Conventional Treatment in Infective Endocarditis", | "EASE" : "Early Surgery versus Conventional Treatment in Infective Endocarditis", | ||
"ISAR-REACT 5" : "Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 5 Trial", | |||
"TRISS" : "Transfusion Requirements in Septic Shock", | "TRISS" : "Transfusion Requirements in Septic Shock", | ||
"TRAPS" : "Trial on Rivaroxaban in AntiPhospholipid Syndrome", | "TRAPS" : "Trial on Rivaroxaban in AntiPhospholipid Syndrome", | ||
| Line 96: | Line 97: | ||
"PRECISION" : "Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen", | "PRECISION" : "Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen", | ||
"AIDA" : "Amsterdam Investigator-Initiated Absorb Strategy All-Comers Trial", | "AIDA" : "Amsterdam Investigator-Initiated Absorb Strategy All-Comers Trial", | ||
"PARTNER 3" : "Placement of Aortic Transcatheter Valves 3", | |||
"V-HeFT" : "Vasodilator Heart Failure Trial", | "V-HeFT" : "Vasodilator Heart Failure Trial", | ||
"EPCAT II" : "Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty II", | "EPCAT II" : "Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty II", | ||
| Line 197: | Line 199: | ||
"CASSINI" : "Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer", | "CASSINI" : "Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer", | ||
"EVOLVE" : "Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis", | "EVOLVE" : "Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis", | ||
"AUGUSTUS" : "An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention", | |||
"FAME" : "Fractional Flow Reserve versus Angiography for Multivessel Evaluation", | "FAME" : "Fractional Flow Reserve versus Angiography for Multivessel Evaluation", | ||
"CHARM-Preserved" : "Candesartan in Heart failure Assessment of Reduction in Mortality and Morbidity-Preserved", | "CHARM-Preserved" : "Candesartan in Heart failure Assessment of Reduction in Mortality and Morbidity-Preserved", | ||
| Line 234: | Line 237: | ||
"IABP-SHOCK II" : "Intraaortic Balloon Pump in Cardiogenic Shock II", | "IABP-SHOCK II" : "Intraaortic Balloon Pump in Cardiogenic Shock II", | ||
"PARTNER 2" : "Placement of Aortic Transcatheter Valves, Cohort A", | "PARTNER 2" : "Placement of Aortic Transcatheter Valves, Cohort A", | ||
"VEST" : "Vest Prevention of Early Sudden Death", | |||
"LoDoCo" : "Low-Dose Colchicine", | "LoDoCo" : "Low-Dose Colchicine", | ||
"CHAMPION PHOENIX" : "Cangrelor versus standard therapy to achieve optimal management of platelet inhibition", | "CHAMPION PHOENIX" : "Cangrelor versus standard therapy to achieve optimal management of platelet inhibition", | ||